YF-Vax

(Yellow Fever vaccine)

ApprovedVaccine

This vaccine protects people from getting yellow fever, a serious disease spread by mosquitoes in tropical and subtropical parts of Africa and South America.[2] YF-Vax is currently approved and in use across 8 indications[4].[1]

YF-Vax is one of 238 biologic programs targeting Toxicity. It is currently in Approved.

Indications

Total Trials

Active Trials

237

Competitors

Pipeline

Status by Indication[4][1]

Indication

ToxicityActive, not recruiting

Rheumatic DiseaseActive, not recruiting

Atopic EczemaActive, not recruiting

Plasmodium Falciparum MalariaActive, not recruiting

ChickenpoxActive, not recruiting

MalariaActive, not recruiting

Hepatitis BActive, not recruiting

ToxicityApproved

Active, not recruiting

Rheumatic DiseasePreclinical

Active, not recruiting

Atopic EczemaPhase 1

Active, not recruiting

Plasmodium Falciparum MalariaPhase 1

Active, not recruiting

ChickenpoxPreclinical

Active, not recruiting

MalariaPhase 3

Active, not recruiting

Hepatitis BPhase 3

Active, not recruiting

Competition

Competitive Landscape

479 competitors in Malaria

#DrugCompanyPhaseTrials

YF-Vax

Sanofi

Approved

1 2

Biltricide

Bayer

Preclinical

1 3

Stelara

Johnson & Johnson

Preclinical

—4

Hydroxychloroquine Sulfate

Novartis

Preclinical

—5

Iron

WWatson Pharmaceuticals

Preclinical

1 6

IV LBH589

Novartis

Preclinical

1 7

IV Ceftriaxone

RRESnTEC, Institute of Research

Preclinical

1 8

Mefloquine Plus Artesunate

Medicines for Malaria Venture

Preclinical

1 9

RTS,S/AS01E

GSK

Preclinical

4 10

Malarone

Medicines for Malaria Venture

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Active, not recruiting

Yellow Fever

NCT05011123

Phase 2Active, not recruiting

Yellow Fever

NCT04942210

Q4 2027

Post-ApprovalActive, not recruiting

Yellow Fever

NCT02555072

Q1 2028

Phase 2Recruiting

Malaria

NCT06879327

Q4 2028

Post-ApprovalRecruiting

Immune Response

NCT06148025

Clinical

Trials by Indication[1]

Yellow Fever8 trials

Study on an Investigational Yellow Fever Vaccine Compared With YF-VAX in Adults in the USA

Active, not recruiting· Sanofi logo

Sanofi·Phase 2·NCT04942210·568 enrolled

Turnover of Antigen Specific Lymphocytes and Monocytes After Immunization With the 17D Yellow Fever Vaccine

Completed·SSri Edupuganti·Phase 4·NCT01290055·27 enrolled

Dose-ranging Study of an Investigational Yellow Fever Candidate Vaccine in Adults

Completed· Sanofi logo

Sanofi·Phase 1·NCT04142086·73 enrolled

Show 5 more trials

Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers

Completed· Sanofi logo

Sanofi·Phase 3·NCT01436396·792 enrolled

Yellow Fever Human Infection Model With YF-17D

Unknown status·LLeiden University Medical Center·N/A·NCT05901454·30 enrolled

Study on an Investigational Yellow Fever Vaccine Compared With Stamaril in Adults in Europe and Asia

Active, not recruiting· Sanofi logo

Sanofi·Phase 2·NCT05011123·690 enrolled

Immunity Period After One Dose of Yellow Fever Vaccine in Adults and Children (Paraiba Study)

Active, not recruiting·TThe Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)·Phase 4·NCT02555072·4,761 enrolled

Non-interference Study of MR and Yellow Fever Vaccines Among Bangladeshi Infants Aged 9-12 Months

Not yet recruiting·IInternational Centre for Diarrhoeal Disease Research, Bangladesh·Phase 3·NCT06815835·1,530 enrolled

Immune Response4 trials

A Study on the Safety, Reactogenicity, and Immune Response to the GVGH iNTS-GMMA Vaccine Against Invasive Nontyphoidal Salmonella in Adults, Children, and Infants

Recruiting· GSK logo

GSK·Phase 2·NCT06213506·516 enrolled

Human Immune Responses to Yellow Fever Vaccination

Completed·EEmory University·Phase 4·NCT00694655·239 enrolled

Antibiotics and Vaccine Immune Responses Study

Recruiting·SSouth Australian Health and Medical Research Institute·Phase 4·NCT06148025·348 enrolled

Show 1 more trial

Yellow Fever Immune Response at Single Cell Resolution

Completed·RRockefeller University··NCT03458780·6 enrolled

Immunogenicity3 trials

A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults

Completed· Novartis logo

Novartis·Phase 3·NCT01466387·552 enrolled

Study of the Safety and Immunogenicity of Reduced Doses of the US Yellow Fever Vaccine

Completed·—·Phase 4·NCT05374317·88 enrolled

A Phase III Control Study of the Safety and Immunogenicity of vYF in Pediatric Population

Recruiting· Sanofi logo

Sanofi·Phase 3·NCT07103148·2,440 enrolled

Vaccination1 trial

The Role of Pre-existing Cross-reactive Antibodies in Determining the Efficacy of Vaccination in Humans

Completed·SSingapore General Hospital·Phase 2·NCT01943305·84 enrolled

Malaria1 trial

Infant Malaria Vaccine Schedule Optimization

Recruiting·PPATH·Phase 2·NCT06879327·1,200 enrolled

9 more indications

Toxicity1 trial

Cytotoxicity of Yellow Fever Specific CD8 T Cells Following YF-17D Vaccination

Active, not recruiting·UUniversity of Aarhus·Phase 4·NCT04083430·60 enrolled

Chickenpox1 trial

Training Study to Characterize Biomarkers to Chickenpox and Yellow Fever Vaccines

Completed·UUniversity of Surrey·N/A·NCT01765413·48 enrolled

Hepatitis B1 trial

Study to Evaluate Immunogenicity of the Hepatitis B Antigen of the GSK Biologicals' Candidate Malaria Vaccine (257049)

Completed· GSK logo

GSK·Phase 3·NCT01345240·705 enrolled

Inflammation1 trial

The Effect of Inflammation and Damage to Lymph Node Structures on Durable Protective Immunity Following Yellow Fever Vaccination

Completed·UUniversity of Minnesota·Phase 1/2·NCT04269265·43 enrolled

Rheumatic Disease1 trial

Yellow Fever Vaccine in Patients With Rheumatic Diseases

Completed·UUniversity of Sao Paulo General Hospital·N/A·NCT03430388·600 enrolled

Double-blind1 trial

Phase 3 Randomized, Modified Double-blind, Active-controlled Safety Study on vYF in Adults

Completed· Sanofi logo

Sanofi·Phase 3·NCT07002060·640 enrolled

Adult1 trial

Phase 3 Single Arm, Open Study on vYF in Adults

Completed· Sanofi logo

Sanofi·Phase 3·NCT07222059·254 enrolled

MMR Vaccine1 trial

Comparison Study of SIBP's MMR Vaccine Versus GSK MMR Vaccine in Children Aged 9-11 Months

Completed·SShanghai Institute Of Biological Products·Phase 3·NCT06399003·1,200 enrolled

Rotavirus Vaccine1 trial

Immune Response to Rotavirus Vaccine After a Supplemental Dose Given at 9 Months of Age With Local EPI Vaccines in Mali

Completed·PPATH·Phase 4·NCT02286895·600 enrolled

Sources

References

[1]
ClinicalTrials.gov — 26 trial records for Yellow Fever vaccine. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — YF-Vax drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Yellow Fever vaccine compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Yellow Fever vaccine. EMBL-EBI & Wellcome Sanger Institute.
[5]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Vaccine[3]
Highest Phase: Approved[1]
Company: Sanofi

YF-Vax

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q4 2027

Q1 2028

Q4 2028

Trials by Indication[1]

Yellow Fever8 trials

Immune Response4 trials

Immunogenicity3 trials

Vaccination1 trial

Malaria1 trial

Toxicity1 trial

Chickenpox1 trial

Hepatitis B1 trial

Inflammation1 trial

Rheumatic Disease1 trial

Double-blind1 trial

Adult1 trial

MMR Vaccine1 trial

Rotavirus Vaccine1 trial

References

Drug Info

Quick Facts

Related News